Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

HPTN 083 demonstrated that injectable cabotegravir (CAB) was superior to oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for HIV prevention in cisgender men and transgender women who have sex with men. We previously analyzed 58 infections in the blinded phase of HPTN 083 (16 in the CAB ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Marzinke, Mark A., Fogel, Jessica M., Wang, Zhe, Piwowar-Manning, Estelle, Kofron, Ryan, Moser, Amber, Bhandari, Pradip, Gollings, Ryann, Bushman, Lane R., Weng, Lei, Halvas, Elias K., Mellors, John, Anderson, Peter L., Persaud, Deborah, Hendrix, Craig W., McCauley, Marybeth, Rinehart, Alex R., St Clair, Marty, Ford, Susan L., Rooney, James F., Adeyeye, Adeola, Chariyalertsak, Suwat, Mayer, Kenneth, Arduino, Roberto C., Cohen, Myron S., Grinsztejn, Beatriz, Hanscom, Brett, Landovitz, Raphael J., Eshleman, Susan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112247/
https://www.ncbi.nlm.nih.gov/pubmed/36995219
http://dx.doi.org/10.1128/aac.00053-23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112247/
https://www.ncbi.nlm.nih.gov/pubmed/36995219
http://dx.doi.org/10.1128/aac.00053-23

Ejemplares similares